Edition:
United States

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

4.35USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$4.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,046
52-wk High
$8.18
52-wk Low
$4.17

Latest Key Developments (Source: Significant Developments)

Sonoma Pharma Revenue $4.8 Million For Third Quarter
Wednesday, 7 Feb 2018 04:05pm EST 

Feb 7 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%.Q3 REVENUE $4.8 MILLION.QTRLY LOSS EARNINGS PER SHARE FROM CONTINUING OPERATIONS $0.73.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 07:05am EST 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article

Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn
Thursday, 16 Nov 2017 07:45am EST 

Nov 16 (Reuters) - Sonoma Pharmaceuticals Inc ::Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language.Approved Alevicyn dermal spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms​.  Full Article

Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million.Q2 revenue $4.3 million versus $2.8 million.Sonoma Pharmaceuticals qtrly loss per share from continuing operations​ $‍0.67.  Full Article

Sonoma Pharmaceuticals receives Brazilian approvals
Tuesday, 31 Oct 2017 07:45am EDT 

Oct 31 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products.Sonoma Pharmaceuticals Inc - ‍is currently seeking to partner with a Brazilian healthcare co relative to licensing newly approved products.Sonoma Pharmaceuticals Inc - ‍issuance of regulatory approvals by Brazilian Ministério Da Saúde for 7 of co's dermatology products​.  Full Article

Sonoma Pharmaceuticals Inc - qtrly‍ net loss per share basic and diluted, continuing operations $0.82​
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports financial results for first quarter of fiscal year 2018.Q1 revenue $3.8 million versus $2.6 million.Sonoma Pharmaceuticals Inc - qtrly ‍net loss per share basic and diluted, continuing operations $0.82​.  Full Article

Sonoma Pharmaceuticals reports qtrly loss per share from continuing operations $ 0.69
Monday, 5 Jun 2017 04:05pm EDT 

June 5 (Reuters) - Sonoma Pharmaceuticals Inc : :Sonoma Pharmaceuticals reports financial results for fourth quarter and fiscal year 2017.Q4 revenue $4.0 million versus $2.6 million.Qtrly loss per share from continuing operations $ 0.69.  Full Article

Sonoma Pharmaceuticals says receives two new UAE regulatory approvals, Pediacyn® for atopic dermatitis and Epicyn® for scar management
Wednesday, 12 Apr 2017 04:05am EDT 

Sonoma Pharmaceuticals Inc : Sonoma Pharmaceuticals - receives two new united arab emirates regulatory approvals: Pediacyn® for atopic dermatitis and Epicyn® for scar management .Sonoma Pharmaceuticals - both offerings, based upon Sonoma's patented Microcyn® Technology hypochlorous acid, will be supplied by MicroSafe Group to UAE beginning in may 2017.  Full Article

Sonoma receives U.S. Fda clearance of Loyon skin descaler
Wednesday, 29 Mar 2017 04:05am EDT 

Sonoma Pharmaceuticals Inc : Sonoma pharmaceuticals receives u.s. Fda clearance of Loyon skin descaler for relief of scaling associated with various dermatoses .U.S. Commercialization via Sonoma's dermatology division Intraderm Pharmaceuticals' 30-plus-person direct sales team is slated for summer 2017.  Full Article

BRIEF-Sonoma Pharma Revenue $4.8 Million For Third Quarter

* SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%